Sudden Infant Death Syndrome (SIDS)

Categories: Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Sudden Infant Death Syndrome

MalaCards integrated aliases for Sudden Infant Death Syndrome:

Name: Sudden Infant Death Syndrome 57 12 73 20 72 29 54 6 42 3 15 17 70 32
Sids 57 12 20 72 3
Sudden Infant Death Syndrome, Susceptibility to 57 13
Sudden Death of Nonspecific Cause in Infancy 12
Death, Sudden, Syndrome, Infant 39
Sudden Infant Death 44
Crib Death 12
Cot Death 12



57 (Updated 05-Apr-2021)
? autosomal recessive form vs. multifactorial


sudden infant death syndrome:
Inheritance autosomal recessive inheritance multifactorial inheritance


External Ids:

Disease Ontology 12 DOID:9007
OMIM® 57 272120
ICD9CM 34 798.0
MeSH 44 D013398
NCIt 50 C85173
SNOMED-CT 67 51178009
ICD10 32 R95
MedGen 41 C0038644
UMLS 70 C0038644

Summaries for Sudden Infant Death Syndrome

MedlinePlus : 42 Sudden infant death syndrome (SIDS) is the sudden, unexplained death of an infant younger than one year old. Some people call SIDS "crib death" because many babies who die of SIDS are found in their cribs. SIDS is the leading cause of death in children between one month and one year old. Most SIDS deaths occur when babies are between one month and four months old. Premature babies, boys, African Americans, and American Indian/Alaska Native infants have a higher risk of SIDS. Although the cause of SIDS is unknown, there are steps you can take to reduce the risk. These include Placing your baby on his or her back to sleep, even for short naps. "Tummy time" is for when babies are awake and someone is watching Having your baby sleep in your room for at least the first six months. Your baby should sleep close to you, but on a separate surface designed for infants, such as a crib or bassinet. Using a firm sleep surface, such as a crib mattress covered with a fitted sheet Keeping soft objects and loose bedding away from your baby's sleep area Breastfeeding your baby Making sure that your baby doesn't get too hot. Keep the room at a comfortable temperature for an adult. Not smoking during pregnancy or allowing anyone to smoke near your baby NIH: National Institute of Child Health and Human Development

MalaCards based summary : Sudden Infant Death Syndrome, also known as sids, is related to short qt syndrome and brugada syndrome, and has symptoms including apnea An important gene associated with Sudden Infant Death Syndrome is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Spironolactone and Clonidine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and lung, and related phenotypes are malignant hyperthermia and apneic episodes in infancy

Disease Ontology : 12 A syndrome that is characterized by the sudden death of an infant that is not predicted by medical history and remains unexplained after a thorough forensic autopsy and detailed death scene investigation.

GARD : 20 Sudden infant death syndrome (SIDS) is the unexpected, sudden death of a child under age 1 which cannot be explained after a thorough investigation is conducted. Infants who are affected by the condition generally appear healthy with no suspicious signs and symptoms prior to the incident. It is the leading cause of death in infants age 1 to 12 months old. The exact underlying cause of SIDS is unknown; however, scientists suspect that it is likely a multifactorial condition (associated with the effects of multiple genes in combination with lifestyle and environmental factors ). Although there is no guaranteed way to prevent SIDS, the American Academy of Pediatrics has a published list of recommendations for risk reduction. Please click on the link to access this resource.

OMIM® : 57 Sudden infant death syndrome (SIDS) is a diagnosis of exclusion which should be made only after a thorough autopsy without identification of a specific cause of death (Mage and Donner, 2004). Weese-Mayer et al. (2007) provided a detailed review of genetic factors that have been implicated in SIDS. The authors concluded that SIDS represents more than 1 entity and has a heterogeneous etiology most likely involving several different genetically controlled metabolic pathways. (272120) (Updated 05-Apr-2021)

CDC : 3 Sudden unexpected infant death (SUID) is a term used to describe the sudden and unexpected death of a baby less than 1 year old in which the cause was not obvious before investigation. These deaths often happen during sleep or in the baby's sleep area. Learn more about the problem and CDC activities.

UniProtKB/Swiss-Prot : 72 Sudden infant death syndrome: SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive.

Wikipedia : 73 Sudden infant death syndrome (SIDS), also known as cot death or crib death, is the sudden unexplained... more...

Related Diseases for Sudden Infant Death Syndrome

Diseases related to Sudden Infant Death Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 short qt syndrome 32.7 SCN5A KCNQ1 KCNH2
2 brugada syndrome 32.5 SNTA1 SCN5A SCN4B LOC110121269 KCNQ1 KCNJ8
3 long qt syndrome 31.8 SNTA1 SCN5A SCN4B LOC110121269 KCNQ1 KCNH2
4 sleep apnea 31.6 SLC6A4 PHOX2B HTR2A
5 cardiac arrhythmia 31.4 SCN5A LOC110121269 KCNQ1 KCNH2
6 familial long qt syndrome 31.4 SNTA1 SCN5A SCN4B LOC110121269 KCNQ1 KCNH2
7 long qt syndrome 1 31.4 SNTA1 SCN5A SCN4B LOC110121269 KCNQ1 KCNJ8
8 long qt syndrome 3 31.2 SNTA1 SCN5A SCN4B LOC110121269 KCNQ1 KCNH2
9 ventricular fibrillation, paroxysmal familial, 1 31.2 SCN5A KCNQ1 KCNH2
10 cardiac arrest 31.1 SCN5A KCNQ1 KCNJ8 KCNH2
11 catecholaminergic polymorphic ventricular tachycardia 31.1 SNTA1 SCN5A SCN4B KCNQ1 KCNJ8 KCNH2
12 central hypoventilation syndrome, congenital 31.0 TH PHOX2B HTR2A
13 syncope 31.0 SCN5A KCNQ1 KCNH2
14 familial short qt syndrome 30.9 KCNQ1 KCNH2
15 sleep disorder 30.8 TH SLC6A4 HTR2A
16 malignant hyperthermia 30.8 SCN5A KCNH2 CAV3
17 right bundle branch block 30.8 SCN5A KCNH2 GPD1L
18 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 30.8 SCN5A KCNQ1 KCNH2
19 brugada syndrome 1 30.7 SCN5A LOC110121269 KCNJ8 KCNH2
20 hypertrophic cardiomyopathy 30.7 SCN5A MT-TL1 MT-ND1 KCNQ1 KCNJ8 KCNH2
21 brugada syndrome 2 30.7 SCN5A GPD1L
22 jervell and lange-nielsen syndrome 1 30.7 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 CAV3
23 long qt syndrome 9 30.7 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 GPD1L
24 long qt syndrome 2 30.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ8 KCNH2
25 atrial fibrillation 30.6 SNTA1 SCN5A SCN4B KCNQ1 KCNH2
26 congenital myasthenic syndrome 30.6 SNTA1 SCN5A KCNQ1 KCNH2 CAV3
27 wolff-parkinson-white syndrome 30.5 SCN5A MT-TL1 KCNQ1
28 left ventricular noncompaction 30.5 SNTA1 SCN5A MT-ND1 LOC110121269 KCNQ1 KCNH2
29 gilles de la tourette syndrome 30.5 TH SLC6A4 HTR2A
30 neuromuscular disease 30.2 SCN5A MT-TL1 KCNH2 CAV3
31 migraine with or without aura 1 30.1 SLC6A4 MT-TL1 HTR2A ADCYAP1
32 cardiomyopathy, infantile histiocytoid 11.4
33 hyperekplexia 11.4
34 infantile apnea 11.3
35 3-hydroxyacyl-coa dehydrogenase deficiency 11.2
36 mitochondrial trifunctional protein deficiency 11.2
37 mucopolysaccharidosis, type ii 11.1
38 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 10.9
39 pertussis 10.6
40 toxic shock syndrome 10.6
41 long qt syndrome 14 10.5 SCN5A KCNQ1 KCNH2
42 diphtheria 10.5
43 developmental and epileptic encephalopathy 14 10.5 SCN5A KCNQ1 KCNH2
44 brugada syndrome 4 10.5 SCN5A KCNQ1 KCNH2
45 sinoatrial node disease 10.5 SCN5A KCNQ1 KCNH2 GPD1L
46 tetanus 10.5
47 myocarditis 10.5
48 myasthenic syndrome, congenital, 5 10.5 SCN5A KCNQ1 KCNH2
49 sick sinus syndrome 1 10.5 SCN5A LOC110121269
50 atrioventricular block 10.5 SCN5A KCNQ1 KCNH2

Graphical network of the top 20 diseases related to Sudden Infant Death Syndrome:

Diseases related to Sudden Infant Death Syndrome

Symptoms & Phenotypes for Sudden Infant Death Syndrome

Human phenotypes related to Sudden Infant Death Syndrome:

# Description HPO Frequency HPO Source Accession
1 malignant hyperthermia 31 HP:0002047
2 apneic episodes in infancy 31 HP:0005949
3 sudden death 31 HP:0001699

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
sudden infant death
malignant hyperthermia association

periodic apnea

Clinical features from OMIM®:

272120 (Updated 05-Apr-2021)

UMLS symptoms related to Sudden Infant Death Syndrome:


MGI Mouse Phenotypes related to Sudden Infant Death Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ADCYAP1 EN1 FEV HTR2A KCNQ1 PHOX2B
2 cardiovascular system MP:0005385 9.85 ACADM CAV3 EN1 KCNH2 KCNJ8 KCNQ1
3 muscle MP:0005369 9.7 ACADM ADCYAP1 CAV3 EN1 HTR2A KCNH2
4 nervous system MP:0003631 9.4 ADCYAP1 EN1 FEV KCNJ8 KCNQ1 PHOX2B

Drugs & Therapeutics for Sudden Infant Death Syndrome

Drugs for Sudden Infant Death Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Clonidine Approved Phase 4 4205-90-7 2803
3 Adrenergic Agents Phase 4
4 Adrenergic Agonists Phase 4
5 Neurotransmitter Agents Phase 4
6 Adrenergic alpha-Agonists Phase 4
7 Mineralocorticoids Phase 4
8 Mineralocorticoid Receptor Antagonists Phase 4
9 Antihypertensive Agents Phase 4
10 Analgesics Phase 4
11 diuretics Phase 4
12 Sympatholytics Phase 4
13 Diuretics, Potassium Sparing Phase 4
14 Anesthetics Phase 4
15 Ophthalmic Solutions Phase 4
16 Plasma-lyte 148 Phase 4
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Ciclesonide Approved, Investigational Phase 3 126544-47-6, 141845-82-1 444033
Adenosine Approved, Investigational Phase 3 58-61-7 60961
Nitric Oxide Approved Phase 3 10102-43-9 145068
Natalizumab Approved, Investigational Phase 3 189261-10-7
25 Mitogens Phase 3
26 Antineoplastic Agents, Immunological Phase 3
27 Hormone Antagonists Phase 3
28 Hormones Phase 3
29 Tubulin Modulators Phase 3
30 Antibiotics, Antitubercular Phase 3
Liposomal doxorubicin Phase 3 31703
32 Antimitotic Agents Phase 3
33 Albumin-Bound Paclitaxel Phase 3
34 Anti-Bacterial Agents Phase 3
35 glucocorticoids Phase 3
36 Anti-Allergic Agents Phase 3
37 Adrenergic beta-Agonists Phase 2
38 AZD-3199 Phase 2
Methamphetamine Approved, Illicit Phase 1 537-46-2 10836
40 Atomoxetine Hydrochloride Phase 1
Chlorhexidine Approved, Vet_approved 55-56-1 2713 9552079
42 Chlorhexidine gluconate
43 Immunologic Factors
44 Pharmaceutical Solutions
45 Immunoglobulins
46 Antibodies
47 Immunoglobulins, Intravenous

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Multicenter Study of Patients With Hypertension Resistant to Patient Identification and Standardization of Therapeutic Unknown status NCT01643434 Phase 4 Spironolactone;Clonidine
2 Effect of Crystalloids With Different SID on Hemodilution, Plasmatic Acid Base Equilibrium and Urinary Electrolytes in Patients During General Anesthesia Recruiting NCT03507062 Phase 4
3 Influence of Pacifiers on Breastfeeding Duration: a Multicentre, Randomised Controlled Trial Completed NCT00306956 Phase 3
4 HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer Completed NCT02040935 Phase 3 Trastuzumab
5 National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer Completed NCT01940497 Phase 3 Doxorubicin;Docetaxel;Paclitaxel;Trastuzumab
6 A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma Completed NCT00546520 Phase 3 Ciclesonide
7 An Open-Label, Randomized, Cross-Over, Multicenter, Phase IIIb Study, to Assess Patients' Tolerability of Trastuzumab Administrated Subcutaneously (SC) Either Via a Single Use Injection Device (SID) or Via Vial for Manual Administration (SC Vial) in Patients With HER2-Positive Early Breast Cancer (eBC) Completed NCT02194166 Phase 3 Trastuzumab;Paclitaxel;Docetaxel
8 Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Recruiting NCT04502030 Phase 3
9 A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration Active, not recruiting NCT03689972 Phase 3 Natalizumab
10 A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC) Completed NCT01401166 Phase 2 Herceptin;Herceptin
11 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma Completed NCT01348139 Phase 2 AZD3199;AZD3199
12 The Period of PURPLE Crying: An Educational Intervention to Change the Knowledge, Attitudes and Behaviour of New Parents About Early Infant Crying Completed NCT00175422 Phase 1, Phase 2
13 A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine Completed NCT02014064 Phase 1 Atomoxetine
14 A Randomized, Open-label, 2-arm, Parallel Group, Single Dose, Multi-center Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of Trastuzumab Administered Subcutaneously as the Trastuzumab/rHuPH20 Formulation Using a Handheld Syringe or Using the Proprietary Single-use Injection Device (SID) Completed NCT01344863 Phase 1 trastuzumab [Herceptin];trastuzumab [Herceptin]
15 Do Pacifiers Protect From Sudden Infant Death Syndrome (SIDS) Through an Increase in Upper Airway Patency? Unknown status NCT01120938
16 The Inclined Position in Case of Respiratory Discomfort in the One Year Less Infant : Study on the Profits and the Risks in the Home Unknown status NCT03482804
17 Sensory Integration (Processing) Disorder Among Children With Behavioral Insomnia and Children With Feeding Disorder Unknown status NCT02040688
18 Changes in Sleep Patterns and Stress in Infants Entering Child Care: Implications for SIDS Risk Completed NCT01265277
19 Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS) Completed NCT00004392
20 A Randomized Controlled Trial Comparing a Children's Book to Brochures for Safe Sleep Education in an At-Risk Population Enrolled in a Home Visitation Program Completed NCT02376673
21 Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS) Completed NCT01361893
22 A Randomized Controlled Trial Pilot Study of the Thirty Million Words® Newborn Initiative Intervention, a Novel Postpartum Educational Video Completed NCT02267265
23 Enhancing Safe Sleep Practices of Urban Low-Income Mothers Completed NCT03070639
24 Parental Knowledge and Beliefs About Infant Sleep Position Completed NCT00005567
25 Evaluation of Safe Sleep for Babies: a Bassinet Distribution and Education Program Completed NCT03392727
26 Post-mortem Cross-sectional Imaging With Guided Biopsy; A Comparative Study With Conventional Autopsy in Foetuses, Neonates, Infants and Children Completed NCT01888380
27 Post Mortem Magnetic Resonance Imaging in the Fetus, Infant and Child: A Comparative Study With Conventional Autopsy Completed NCT01417962
28 Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England: a Quasi-experimental Study Completed NCT02039583
29 Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands Completed NCT02189265
30 A Randomized Controlled Trial of The Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance: the Suzuki Music Model Applied to Urban Pediatrics Completed NCT01014169
31 Quality Assurance on Diagnosis and Therapy of Secondary Immunodeficiencies (SID) in Patients With Chronic Lymphocytic Leukemia (CLL) or Multiple Myeloma (MM) in Germany (QS-SID) Completed NCT04172467
32 Improving Infant Sleep Safety With the Electronic Health Record: Using Infant Photographs Taken by Parents for Individualized Feedback Completed NCT03662048
33 Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors Recruiting NCT03278977
34 Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise Recruiting NCT03775954
35 Generations in Families Talking Safe Sleep Active, not recruiting NCT03186469
36 A CBPR Initiative for Reducing Infant Mortality In American Indian Communities Active, not recruiting NCT03494621
37 Safety, Tolerability, and Patient Satisfaction of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment by Rapid Push in Patients With Primary or Secondary Immunodeficiency (PID or SID) Not yet recruiting NCT04354129 Cutaquig®

Search NIH Clinical Center for Sudden Infant Death Syndrome

Cochrane evidence based reviews: sudden infant death

Genetic Tests for Sudden Infant Death Syndrome

Genetic tests related to Sudden Infant Death Syndrome:

# Genetic test Affiliating Genes
1 Sudden Infant Death Syndrome 29 SCN5A

Anatomical Context for Sudden Infant Death Syndrome

MalaCards organs/tissues related to Sudden Infant Death Syndrome:

Brain, Heart, Lung, Breast, Liver, Medulla Oblongata, Thymus

Publications for Sudden Infant Death Syndrome

Articles related to Sudden Infant Death Syndrome:

(show top 50) (show all 6148)
# Title Authors PMID Year
A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. 6 57 61
16453024 2006
Mitochondrial DNA point mutations detected in four cases of sudden infant death syndrome. 61 57 6
10519336 1999
Sudden Infant Death Syndrome: review of implicated genetic factors. 54 61 57
17340630 2007
Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. 61 54 57
17275750 2007
The sudden infant death syndrome gene: does it exist? 57 54 61
15466077 2004
Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. 61 54 57
11710892 2001
Serotonin transporter gene variation is a risk factor for sudden infant death syndrome in the Japanese population. 61 54 57
11335745 2001
Homing in on a SIDS model. 61 57
18988825 2008
Sporadic autonomic dysregulation and death associated with excessive serotonin autoinhibition. 61 57
18599790 2008
The fifty percent male excess of infant respiratory mortality. 61 57
15384886 2004
Distinct cytokine profile in SIDS brain: a common denominator in a multifactorial syndrome? 57 61
14610131 2003
Association of the serotonin transporter gene with sudden infant death syndrome: a haplotype analysis. 57 61
12966525 2003
Sudden infant death syndrome: association with a promoter polymorphism of the serotonin transporter gene. 61 57
12599191 2003
Molecular diagnosis in a child with sudden infant death syndrome. 57 61
11684219 2001
A molecular link between the sudden infant death syndrome and the long-QT syndrome. 61 57
10911008 2000
Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: relationship with sudden infant death syndrome. 61 57
10813596 2000
Prolonged QTc as a risk factor for SIDS. 61 57
10103309 1999
The implications of a relationship between prolonged QT interval and the sudden infant death syndrome. 61 57
10103310 1999
Prolongation of the QT interval and the sudden infant death syndrome. 57 61
10103308 1999
Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. 57 61
9627580 1998
Prolongation of the QT interval and the sudden infant death syndrome. 57 61
9624190 1998
Cytochrome P-450 expression in sudden infant death syndrome. 57 61
8687505 1996
Decreased muscarinic receptor binding in the arcuate nucleus in sudden infant death syndrome. 61 57
7660131 1995
The mystery of SIDS. A murder conviction revives questions about infant deaths. 57 61
7652525 1995
Multiple 'SIDS' case ruled murder. 57 61
7725090 1995
Arcuate nucleus hypoplasia in the sudden infant death syndrome. 57 61
1619439 1992
Death-scene investigation in sudden infant death. 57 61
3724796 1986
Simultaneous sudden infant death syndrome in twins. 61 57
3754958 1986
QT interval measurements before sudden infant death syndrome. 61 57
3707181 1986
Incidence of apnea in siblings of sudden infant death syndrome victims studied at home. 61 57
7088613 1982
Potential role of QT interval prolongation in sudden infant death syndrome. 61 57
947572 1976
Prolonged apnea and the sudden infant death syndrome: clinical and laboratory observations. 61 57
4342142 1972
Sudden Infant Death Syndrome on Facebook: Qualitative Descriptive Content Analysis to Guide Prevention Efforts. 61 42
32729842 2020
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. 6
18378609 2008
SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. 6
12471205 2002
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. 6
12193783 2002
About the "Pathological" role of the mtDNA T3308C mutationellipsis. 6
10521313 1999
Comments on a sudden infant death article in another journal. 57
10103306 1999
Somatic mutations of the mitochondrial genome in human colorectal tumours. 6
9806551 1998
The long QT syndrome in children. An international study of 287 patients. 57
8099317 1993
Clinical features of the idiopathic long QT syndrome. 57
1345816 1992
Primary alveolar hypoventilation (Ondine's curse syndrome) in an infant without external arcuate nucleus. Case report. 57
497494 1979
On the origin of cancer cells. 6
13298683 1956
Recurrent sudden unexpected death in infancy: a case series of sibling deaths. 42
32527717 2020
Comparing Bayesian spatial models: Goodness-of-smoothing criteria for assessing under- and over-smoothing. 42
32433653 2020
Amniotic fluid aspiration in cases of SIDS. 61 54
19904550 2010
The role of 5-HT3 and other excitatory receptors in central cardiorespiratory responses to hypoxia: implications for sudden infant death syndrome. 54 61
19247214 2009
A985G mutation incidence in the medium-chain acyl-CoA dehydrogenase (MCAD) gene in Brazil. 54 61
19551636 2009
Sudden infant death syndrome (SIDS) in African Americans: polymorphisms in the gene encoding the stress peptide pituitary adenylate cyclase-activating polypeptide (PACAP). 61 54
19120039 2009
Association of dopamine transporter and monoamine oxidase molecular polymorphisms with sudden infant death syndrome and stillbirth: new insights into the serotonin hypothesis. 61 54
18810510 2009

Variations for Sudden Infant Death Syndrome

ClinVar genetic disease variations for Sudden Infant Death Syndrome:

6 (show all 46)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MT-TL1 m.3290T>C SNV Pathogenic 9597 rs199474665 GRCh37: MT:3290-3290
GRCh38: MT:3290-3290
2 MT-ND1 m.3308T>G SNV Pathogenic 9729 rs28358582 GRCh37: MT:3308-3308
GRCh38: MT:3308-3308
3 MT-ND1 m.3308T>C SNV Pathogenic 9728 rs28358582 GRCh37: MT:3308-3308
GRCh38: MT:3308-3308
4 LOC110121269 , SCN5A NM_000335.5(SCN5A):c.3305C>A (p.Ser1102Tyr) SNV Pathogenic 9393 rs7626962 GRCh37: 3:38620907-38620907
GRCh38: 3:38579416-38579416
5 SCN5A NM_198056.2(SCN5A):c.1099C>T (p.Arg367Cys) SNV Pathogenic 67633 rs199473097 GRCh37: 3:38648201-38648201
GRCh38: 3:38606710-38606710
6 SCN5A NM_000335.5(SCN5A):c.665G>A (p.Arg222Gln) SNV Pathogenic 39444 rs45546039 GRCh37: 3:38655272-38655272
GRCh38: 3:38613781-38613781
7 SCN5A NM_198056.2(SCN5A):c.5872C>T (p.Arg1958Ter) SNV Pathogenic 201546 rs757532106 GRCh37: 3:38591991-38591991
GRCh38: 3:38550500-38550500
8 KCNQ1 NM_000218.3(KCNQ1):c.820A>G (p.Ile274Val) SNV Likely pathogenic 67109 rs199472728 GRCh37: 11:2594115-2594115
GRCh38: 11:2572885-2572885
9 SCN5A NM_000335.5(SCN5A):c.5474G>A (p.Arg1825His) SNV Uncertain significance 9389 rs137854610 GRCh37: 3:38592386-38592386
GRCh38: 3:38550895-38550895
10 SCN5A NM_198056.2(SCN5A):c.1595T>G (p.Phe532Cys) SNV Uncertain significance 67671 rs199473573 GRCh37: 3:38645498-38645498
GRCh38: 3:38604007-38604007
11 SCN4B NM_174934.3(SCN4B):c.617C>T (p.Ser206Leu) SNV Uncertain significance 191380 rs140348243 GRCh37: 11:118007812-118007812
GRCh38: 11:118137097-118137097
12 LOC110121269 , SCN5A NM_000335.5(SCN5A):c.2989G>A (p.Ala997Thr) SNV Uncertain significance 67771 rs137854609 GRCh37: 3:38622661-38622661
GRCh38: 3:38581170-38581170
13 SCN5A NM_000335.5(SCN5A):c.5901C>G (p.Ile1967Met) SNV Uncertain significance 68018 rs199473333 GRCh37: 3:38591959-38591959
GRCh38: 3:38550468-38550468
14 SCN5A NM_198056.2(SCN5A):c.5803G>A (p.Gly1935Ser) SNV Uncertain significance 68011 rs199473637 GRCh37: 3:38592060-38592060
GRCh38: 3:38550569-38550569
15 SCN5A NM_198056.2(SCN5A):c.5738G>A (p.Arg1913His) SNV Uncertain significance 68009 rs199473327 GRCh37: 3:38592125-38592125
GRCh38: 3:38550634-38550634
16 SCN5A NM_000335.4(SCN5A):c.5686C>T (p.Arg1896Trp) SNV Uncertain significance 68003 rs45465995 GRCh37: 3:38592174-38592174
GRCh38: 3:38550683-38550683
17 SCN5A NM_000335.5(SCN5A):c.4783T>A (p.Phe1595Ile) SNV Uncertain significance 67924 rs199473278 GRCh37: 3:38595797-38595797
GRCh38: 3:38554306-38554306
18 LOC110121269 , SCN5A NM_198056.2(SCN5A):c.2924G>A (p.Arg975Gln) SNV Uncertain significance 201483 rs753149586 GRCh37: 3:38622726-38622726
GRCh38: 3:38581235-38581235
19 SCN5A NM_000335.4(SCN5A):c.1282G>A (p.Glu428Lys) SNV Uncertain significance 30048 rs199473111 GRCh37: 3:38647498-38647498
GRCh38: 3:38606007-38606007
20 SCN5A NM_198056.2(SCN5A):c.5795C>T (p.Ala1932Val) SNV Uncertain significance 582721 rs371194826 GRCh37: 3:38592068-38592068
GRCh38: 3:38550577-38550577
21 SCN5A NM_000335.5(SCN5A):c.5783G>A (p.Arg1928His) SNV Uncertain significance 179372 rs727504822 GRCh37: 3:38592077-38592077
GRCh38: 3:38550586-38550586
22 SCN5A NM_000335.5(SCN5A):c.3553G>A (p.Ala1185Thr) SNV Uncertain significance 67802 rs199473595 GRCh37: 3:38616898-38616898
GRCh38: 3:38575407-38575407
23 LOC110121269 , SCN5A NM_198056.2(SCN5A):c.3118G>A (p.Gly1040Arg) SNV Uncertain significance 67779 rs199473186 GRCh37: 3:38622532-38622532
GRCh38: 3:38581041-38581041
24 LOC110121269 , SCN5A NM_198056.2(SCN5A):c.3080G>A (p.Arg1027Gln) SNV Uncertain significance 520458 rs763891399 GRCh37: 3:38622570-38622570
GRCh38: 3:38581079-38581079
25 SCN5A NM_000335.5(SCN5A):c.152C>T (p.Ala51Val) SNV Uncertain significance 179791 rs727505131 GRCh37: 3:38674647-38674647
GRCh38: 3:38633156-38633156
26 SCN5A NM_000335.5(SCN5A):c.880G>A (p.Val294Met) SNV Uncertain significance 68054 rs199473086 GRCh37: 3:38651279-38651279
GRCh38: 3:38609788-38609788
27 KCNQ1 NM_181798.1(KCNQ1):c.997G>A (p.Gly333Ser) SNV Uncertain significance 67031 rs199472783 GRCh37: 11:2610069-2610069
GRCh38: 11:2588839-2588839
28 SCN5A NM_198056.2(SCN5A):c.2399G>A (p.Arg800His) SNV Uncertain significance 222807 rs566251672 GRCh37: 3:38628928-38628928
GRCh38: 3:38587437-38587437
29 GPD1L NM_015141.4(GPD1L):c.370A>G (p.Ile124Val) SNV Likely benign 788 rs72552293 GRCh37: 3:32181723-32181723
GRCh38: 3:32140231-32140231
30 KCNJ8 NM_004982.4(KCNJ8):c.1001T>C (p.Val334Ala) SNV Benign 137998 rs34811413 GRCh37: 12:21918931-21918931
GRCh38: 12:21765997-21765997
31 KCNJ8 NM_004982.4(KCNJ8):c.793T>C (p.Leu265=) SNV Benign 221022 rs16924297 GRCh37: 12:21919139-21919139
GRCh38: 12:21766205-21766205
32 KCNQ1 NM_181798.1(KCNQ1):c.1369G>A (p.Gly457Ser) SNV not provided 67054 rs199472811 GRCh37: 11:2799223-2799223
GRCh38: 11:2777993-2777993
33 KCNH2 NM_000238.3(KCNH2):c.2684C>T (p.Thr895Met) SNV not provided 67426 rs199473434 GRCh37: 7:150645540-150645540
GRCh38: 7:150948452-150948452
34 KCNQ1 NM_181798.1(KCNQ1):c.754T>C (p.Trp252Arg) SNV not provided 67013 rs199472768 GRCh37: 11:2608806-2608806
GRCh38: 11:2587576-2587576
35 KCNH2 NM_000238.4(KCNH2):c.2860C>T (p.Arg954Cys) SNV not provided 67444 rs141401803 GRCh37: 7:150644799-150644799
GRCh38: 7:150947711-150947711
36 SCN5A NM_000335.5(SCN5A):c.2039G>A (p.Arg680His) SNV not provided 67706 rs199473142 GRCh37: 3:38639443-38639443
GRCh38: 3:38597952-38597952
37 SCN5A NM_198056.2(SCN5A):c.1076C>A (p.Ala359Asp) SNV not provided 440929 rs1553704925 GRCh37: 3:38648224-38648224
GRCh38: 3:38606733-38606733
38 KCNH2 NM_000238.3(KCNH2):c.3118A>G (p.Ser1040Gly) SNV not provided 67472 rs199473024 GRCh37: 7:150644450-150644450
GRCh38: 7:150947362-150947362
39 KCNH2 NM_172056.2(KCNH2):c.881G>T (p.Gly294Val) SNV not provided 67539 rs199473549 GRCh37: 7:150655182-150655182
GRCh38: 7:150958094-150958094
40 KCNQ1 NM_181798.1(KCNQ1):c.1412A>G (p.Lys471Arg) SNV not provided 67056 rs199472817 GRCh37: 11:2799266-2799266
GRCh38: 11:2778036-2778036
41 KCNH2 NM_172056.2(KCNH2):c.818G>A (p.Arg273Gln) SNV not provided 67531 rs199472877 GRCh37: 7:150655245-150655245
GRCh38: 7:150958157-150958157
42 KCNH2 NM_172056.2(KCNH2):c.835G>A (p.Val279Met) SNV not provided 67534 rs199472879 GRCh37: 7:150655228-150655228
GRCh38: 7:150958140-150958140
43 LOC110121269 , SCN5A NM_001160161.1(SCN5A):c.3228+1457G>A SNV not provided 67786 rs199473190 GRCh37: 3:38620965-38620965
GRCh38: 3:38579474-38579474
44 SCN5A NM_000335.4(SCN5A):c.4453T>C (p.Phe1485Leu) SNV not provided 67894 rs199473615 GRCh37: 3:38597233-38597233
GRCh38: 3:38555742-38555742
45 SCN5A NM_000335.4(SCN5A):c.5111T>C (p.Phe1704Ser) SNV not provided 67954 rs199473627 GRCh37: 3:38592749-38592749
GRCh38: 3:38551258-38551258
46 KCNH2 NM_000238.3(KCNH2):c.3470C>T (p.Pro1157Leu) SNV not provided 67499 rs143167166 GRCh37: 7:150642463-150642463
GRCh38: 7:150945375-150945375

UniProtKB/Swiss-Prot genetic disease variations for Sudden Infant Death Syndrome:

# Symbol AA change Variation ID SNP ID
1 CAV3 p.Val14Leu VAR_043694 rs121909281
2 CAV3 p.Thr78Met VAR_043695 rs72546668
3 CAV3 p.Leu79Arg VAR_043696 rs121909282
4 KCNJ8 p.Val346Ile VAR_065879 rs147316959
5 SCN5A p.Ser1333Tyr VAR_036666 rs199473604
6 SCN5A p.Phe532Cys VAR_055177 rs199473573
7 SCN5A p.Phe1705Ser VAR_055207 rs199473627

Expression for Sudden Infant Death Syndrome

Search GEO for disease gene expression data for Sudden Infant Death Syndrome.

Pathways for Sudden Infant Death Syndrome

GO Terms for Sudden Infant Death Syndrome

Cellular components related to Sudden Infant Death Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.5 KCNQ1 KCNJ8 KCNH2
2 caveola GO:0005901 9.43 SCN5A HTR2A CAV3
3 dystrophin-associated glycoprotein complex GO:0016010 9.4 SNTA1 CAV3
4 voltage-gated sodium channel complex GO:0001518 9.37 SCN5A SCN4B
5 lateral plasma membrane GO:0016328 9.33 SNTA1 SCN5A KCNQ1
6 intercalated disc GO:0014704 9.13 SCN5A SCN4B CAV3
7 sarcolemma GO:0042383 8.92 SNTA1 SCN5A KCNJ8 CAV3

Biological processes related to Sudden Infant Death Syndrome according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 TH SLC6A4 MT-ND1 HTR2A
2 sodium ion transmembrane transport GO:0035725 9.83 SLC6A4 SCN5A SCN4B
3 regulation of ion transmembrane transport GO:0034765 9.8 SCN5A SCN4B KCNQ1 KCNJ8 KCNH2
4 memory GO:0007613 9.79 TH SLC6A4 HTR2A
5 cellular response to drug GO:0035690 9.75 TH KCNQ1 KCNH2
6 social behavior GO:0035176 9.71 TH SLC6A4 EN1
7 cardiac conduction GO:0061337 9.7 SCN5A KCNQ1 KCNH2
8 regulation of heart contraction GO:0008016 9.67 TH KCNQ1 CAV3
9 cardiac muscle contraction GO:0060048 9.67 SCN5A SCN4B KCNQ1 KCNH2
10 membrane depolarization during action potential GO:0086010 9.66 SCN5A KCNH2
11 cardiac muscle cell action potential involved in contraction GO:0086002 9.65 SCN5A SCN4B
12 potassium ion export across plasma membrane GO:0097623 9.65 KCNQ1 KCNH2
13 regulation of sodium ion transmembrane transporter activity GO:2000649 9.65 SCN4B GPD1L CAV3
14 positive regulation of potassium ion transmembrane transport GO:1901381 9.64 KCNQ1 KCNH2
15 neurotransmitter biosynthetic process GO:0042136 9.64 TH SLC6A4
16 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.63 SCN5A SCN4B
17 negative regulation of potassium ion transmembrane transport GO:1901380 9.63 KCNH2 CAV3
18 positive regulation of sodium ion transport GO:0010765 9.63 SCN5A SCN4B GPD1L
19 membrane repolarization GO:0086009 9.62 KCNQ1 KCNH2
20 regulation of membrane repolarization GO:0060306 9.62 KCNQ1 KCNH2
21 regulation of heart rate by cardiac conduction GO:0086091 9.62 SCN5A SCN4B KCNQ1 KCNH2
22 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.61 KCNQ1 KCNH2
23 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.61 KCNQ1 KCNJ8 KCNH2
24 atrial cardiac muscle cell action potential GO:0086014 9.6 SCN5A KCNQ1
25 membrane repolarization during action potential GO:0086011 9.59 KCNQ1 KCNH2
26 negative regulation of potassium ion transport GO:0043267 9.58 HTR2A ADCYAP1
27 regulation of sodium ion transmembrane transport GO:1902305 9.57 SNTA1 SCN5A
28 brainstem development GO:0003360 9.56 SCN5A PHOX2B
29 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.55 SCN5A KCNQ1
30 AV node cell action potential GO:0086016 9.51 SCN5A SCN4B
31 regulation of heart rate GO:0002027 9.46 SNTA1 SCN5A GPD1L CAV3
32 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.43 SCN5A GPD1L CAV3
33 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.43 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 CAV3
34 ventricular cardiac muscle cell action potential GO:0086005 9.1 SNTA1 SCN5A KCNQ1 KCNH2 GPD1L CAV3

Molecular functions related to Sudden Infant Death Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated ion channel activity GO:0005244 9.65 SCN5A SCN4B KCNQ1 KCNJ8 KCNH2
2 scaffold protein binding GO:0097110 9.58 SCN5A KCNQ1 KCNH2
3 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.5 KCNQ1 KCNJ8 KCNH2
4 inward rectifier potassium channel activity GO:0005242 9.48 KCNJ8 KCNH2
5 serotonin binding GO:0051378 9.46 SLC6A4 HTR2A
6 sodium channel regulator activity GO:0017080 9.46 SNTA1 SCN4B GPD1L CAV3
7 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.43 KCNQ1 KCNH2
8 ion channel binding GO:0044325 9.43 SNTA1 SCN5A SCN4B KCNQ1 GPD1L CAV3
9 voltage-gated sodium channel activity involved in cardiac muscle cell action potential GO:0086006 9.37 SCN5A SCN4B
10 nitric-oxide synthase binding GO:0050998 8.92 SNTA1 SLC6A4 SCN5A CAV3

Sources for Sudden Infant Death Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....